Pharmaceuticals
CSafe Global Launches an Industry First: Real-Time Shipment Visibility
CSafe Global continues to focus on innovating temperature-controlled container solutions with the launch of 24/7 real-time shipment visibility. DAYTON, Ohio, Dec. 1, 2020 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled container solutions for the transport of lif...
RxLogix Acclaimed by Frost & Sullivan for its Best-in-class Pharmacovigilance Solution, PV Intake & Processing
SANTA CLARA, Calif., Dec. 1, 2020 /PRNewswire/ -- Based on its recent analysis of the global pharmacovigilance (PV) automation software market, Frost & Sullivan recognizesRxLogix Corporation with the 2020 Global Product Leadership Award for its PV Intake & Processing (PVIP) solution. The Product ...
AGC Biologics to Expand Biopharmaceutical CDMO Capacity
Doubling the production capacity at its site in Denmark to address strong demand SEATTLE, Dec. 1, 2020 /PRNewswire/ -- AGC Biologics announced that it will increase the production capacity of itsCopenhagen facility. AGC Biologics will construct a new building on land adjacent to its currentCopenh...
ORTHO Optix™ Reader Now Available in CE Mark Countries, Completes Transfusion Medicine Portfolio
RARITAN, N.J., Dec. 1, 30, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today announced the CE Mark availability of the semi-automated ORTHO Optix™ Reader, which allows lo...
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®
NEW YORK and BLAINVILLE, QC, Nov. 30, 2020 /PRNewswire/ -- Today the Population Council and Duchesnay announce an exclusive license agreement to make ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive fully under a woman's control to protect aga...
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19
RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new collaborations follow recently announced collaborations with European and Canadian manufacturers U.S. Pha...
Gilead Sciences' Pulse Survey Highlights Majority of People Living with HIV, Individuals at Risk and HIV Care Prescribers in Asia Pacific Experience Disruptions in HIV Care During COVID-19 Pandemic
HONG KONG, Nov. 30, 2020 /PRNewswire/ -- Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, inAsia Pacific. The survey revealed ...
Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology
SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced it has entered into an ag...
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer
SHANGHAI, Nov. 30, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that Melissa Palmer, MD, an internationally renowned Hepatologist, will join the Compa...
Varian Partners with Sony Foundation Australia in the You Can Stay Program
PALO ALTO, Calif., Nov. 30, 2020 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has entered a partnership with Sony Foundation Australia to support its You Can Stay Program. The You Can Stay program provides free accommodations for cancer patients aged between 15 to 25 and their families i...
Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08:00 a.m. Finnish time
HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, on...
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
DARMSTADT, Germany, Nov. 27, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
TAIPEI, Nov. 26, 2020 /PRNewswire/ -- Golden Biotechnology Corp.(GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol (HOCENA®) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in ...
Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness
* Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines * Two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative SHANGHAI, Nov. 26, 2020 ...
Interim report, May-October 2020/21
STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony...
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations
TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple Investigational New D...
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...
Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone
SIR-Spheres® new drug application is accepted by the National Medical Products Administration of China WOBURN, Mass., Nov. 26, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareh...
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical ...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00